OBJECTIVES: To describe the predictive utility of the D-dimer assay among patients with the coronavirus disease 2019 syndrome for unprovoked lower extremity deep venous thrombosis. DESIGN: Prospective observational study with retrospective data analysis. SETTING: Academic medical center surgical ICU. PATIENTS: Seventy-two intubated patients with critical illness from coronavirus disease 2019. INTERVENTIONS: Therapeutic anticoagulation after imaging diagnosis of the first three deep venous thrombosis cases was confirmed; therapeutic anticoagulation as prophylaxis thereafter to all subsequent ICU admissions. MEASUREMENTS AND MAIN RESULTS: Seventy-two patients with severe coronavirus disease 2019 were screened for deep venous thrombosis after ICU admission with 102 duplex ultrasound examinations, with 12 cases (16.7%) of lower extremity deep venous thrombosis identified. There were no differences between groups with respect to age, renal function, or biomarkers except for D-dimer (median, 12,858 ng/mL [interquartile range, 3,176-30,770 ng/mL] for lower extremity deep venous thrombosis vs 2,087 ng/mL [interquartile range, 638-3,735 ng/mL] for no evidence of deep venous thrombosis; p < 0.0001). Clinical screening tools (Wells score and Dutch Primary Care Rule) had no utility. The C-statistic for D-dimer concentration was 0.874 ± 0.065. At the model-predicted cutoff value of 3,000 ng/mL, sensitivity was 100%, specificity was 51.1%, positive predictive value was 21.8%, and negative predictive value was 100%. CONCLUSIONS: Lower extremity deep venous thrombosis is prevalent in coronavirus disease 2019 disease and can be present on ICU admission. Screening has been recommended in the context of the pro-inflammatory, hypercoagulable background milieu. D-dimer concentrations are elevated in nearly all coronavirus disease 2019 patients, and the test appears reliable for screening for lower extremity deep venous thrombosis at or above a concentration of 3,000 ng/mL (more than 13-fold above the normal range). Full anticoagulation is indicated if the diagnosis is confirmed, and therapeutic anticoagulation should be considered for prophylaxis, as all coronavirus disease 2019 patients are at increased risk.
OBJECTIVES: To describe the predictive utility of the D-dimer assay among patients with the coronavirus disease 2019 syndrome for unprovoked lower extremity deep venous thrombosis. DESIGN: Prospective observational study with retrospective data analysis. SETTING: Academic medical center surgical ICU. PATIENTS: Seventy-two intubated patients with critical illness from coronavirus disease 2019. INTERVENTIONS: Therapeutic anticoagulation after imaging diagnosis of the first three deep venous thrombosis cases was confirmed; therapeutic anticoagulation as prophylaxis thereafter to all subsequent ICU admissions. MEASUREMENTS AND MAIN RESULTS: Seventy-two patients with severe coronavirus disease 2019 were screened for deep venous thrombosis after ICU admission with 102 duplex ultrasound examinations, with 12 cases (16.7%) of lower extremity deep venous thrombosis identified. There were no differences between groups with respect to age, renal function, or biomarkers except for D-dimer (median, 12,858 ng/mL [interquartile range, 3,176-30,770 ng/mL] for lower extremity deep venous thrombosis vs 2,087 ng/mL [interquartile range, 638-3,735 ng/mL] for no evidence of deep venous thrombosis; p < 0.0001). Clinical screening tools (Wells score and Dutch Primary Care Rule) had no utility. The C-statistic for D-dimer concentration was 0.874 ± 0.065. At the model-predicted cutoff value of 3,000 ng/mL, sensitivity was 100%, specificity was 51.1%, positive predictive value was 21.8%, and negative predictive value was 100%. CONCLUSIONS:Lower extremity deep venous thrombosis is prevalent in coronavirus disease 2019 disease and can be present on ICU admission. Screening has been recommended in the context of the pro-inflammatory, hypercoagulable background milieu. D-dimer concentrations are elevated in nearly all coronavirus disease 2019patients, and the test appears reliable for screening for lower extremity deep venous thrombosis at or above a concentration of 3,000 ng/mL (more than 13-fold above the normal range). Full anticoagulation is indicated if the diagnosis is confirmed, and therapeutic anticoagulation should be considered for prophylaxis, as all coronavirus disease 2019patients are at increased risk.
Authors: Irene Mollinedo-Gajate; Felipe Villar-Álvarez; María de Los Ángeles Zambrano-Chacón; Laura Núñez-García; Laura de la Dueña-Muñoz; Carlos López-Chang; Miguel Górgolas; Alfonso Cabello; Olga Sánchez-Pernaute; Fredeswinda Romero-Bueno; Álvaro Aceña; Nicolás González-Mangado; Germán Peces-Barba; Faustino Mollinedo Journal: Crit Care Explor Date: 2021-02-22
Authors: Ljiljana V Vasovic; James Littlejohn; Dalia Alqunaibit; Alicia Dillard; Yuqing Qiu; Sophie Rand; Matthew Bronstein; Cameron J Gibson; Anton G Kelly; Christina Lee; Jennifer A Minneman; Mayur Narayan; Jian Shou; Kira E Smith; Cassandra V Villegas; Robert J Winchell; Melissa M Cushing; Philip S Barie Journal: Surgery Date: 2021-09-09 Impact factor: 3.982
Authors: José Antonio Rueda-Camino; Vanesa Sendín-Martín; María Dolores Joya-Seijo; María Angelina-García; Celia Zamarro-García; Francisco Javier Gimena-Rodríguez; Raquel Barba-Martín Journal: Med Clin (Engl Ed) Date: 2022-04-23
Authors: José Antonio Rueda-Camino; Vanesa Sendín-Martín; María Dolores Joya-Seijo; María Angelina-García; Celia Zamarro-García; Francisco Javier Gimena-Rodríguez; Raquel Barba-Martín Journal: Med Clin (Barc) Date: 2021-06-03 Impact factor: 1.725
Authors: Hervé Lobbes; Sabine Mainbourg; Vicky Mai; Marion Douplat; Steeve Provencher; Jean-Christophe Lega Journal: Int J Environ Res Public Health Date: 2021-12-08 Impact factor: 3.390